Nuclear respiratory factor-1 negatively regulates TGF-β1 and attenuates pulmonary fibrosis

Highlights
ReCORM reduces lung fibrosis in a bleomycin (BLM) model and improves lung function
ReCORM increases antifibrotic and decreases profibrotic genes expression via NRF-1/HO-1
ReCORM preserves mitochondrial function and decreases cell death after BLM exposure
ReCORM reduced lung inflammation and protected lung epithelial cells after BLM exposure
Nuclear respiratory factor-1 negatively regulates TGF-β1 and attenuates pulmonary fibrosis

Hagir B. Suliman,1,2,3,5,* Zachary Healy,1 Fabio Zobi,4 Bryan D. Kraft,1 Karen Welty-Wolf,1 Joshua Smith,1 Christina Barkauskas,1 and Claude A. Piantadosi1,2,3

SUMMARY
The preclinical model of bleomycin-induced lung fibrosis is useful to study mechanisms related to human pulmonary fibrosis. Using BLM in mice, we find low HO-1 expression. Although a unique Rhenium-CO-releasing molecule (ReCORM) upregulates HO-1, NRF-1, CCN5, and SMAD7, it reduces TGFβ1, TGFβr1, collagen, α-SMA, and phosphorylated Smad2/3 levels in mouse lung and in human lung fibroblasts. ChIP assay studies confirm NRF-1 binding to the promoters of TGFβ1 repressors CCN5 and Smad7. ReCORM did not blunt lung fibrosis in Hmox1-deficient alveolar type 2 cell knockout mice, suggesting this gene participates in lung protection. In human lung fibroblasts, TGFβ1-dependent production of α-SMA is abolished by ReCORM or by NRF-1 gene transfection. We demonstrate effective HO-1/NRF-1 signaling in lung AT2 cells protects against BLM induced lung injury and fibrosis by maintaining mitochondrial health, function, and suppressing the TGFβ1 pathway. Thus, protection of AT2 cell mitochondrial integrity via HO-1/NRF-1 presents an innovative therapeutic target.

INTRODUCTION
Pulmonary fibrosis (PF) is a life-threatening pulmonary disease featuring heterogeneous denudation of alveolar epithelium, fibroblast proliferation (Wynn, 2011), excessive collagen, and matrix deposition in the lung. Current therapy is based on empirical anti-fibrotic agents, which have limited benefits and significant side effects (Borgeson et al., 2011). Though the mechanisms of PF are not fully understood, mitochondrial damage and dysfunction has emerged as a key pathogenic factor in the disease (Rangarajan et al., 2017). Furthermore, chronic alveolar injury and dysregulation of parenchymal repair leading to collagen and matrix deposition occur (Wuyts et al., 2013). In addition, oxidative stress especially from mitochondrial oxidants can cause alveolar epithelial (AEC) cell death in animal models (Gazdhar et al., 2014; Yeung et al., 2015).

AEC loss activates sub-epithelial fibroblasts and promotes PF, in part by upregulating transforming growth factor β1 (TGFβ1) in immune cells (Funke et al., 2012; Wynn, 2011). TGFβ1 released by lymphocytes and macrophages causes fibroblasts to differentiate through receptor-mediated Smad-dependent and Smad-independent pathways, over-expressing α-smooth muscle actin (α-SMA), and generating extracellular matrix proteins (Wolters et al., 2014). TGFβ1 is also implicated in apparent epithelial to mesenchymal transition (Gorowiec et al., 2012), which has been proposed as a causal factor in the development of PF (Semren et al., 2015). CCN5 also known as WISP-2 is a transcriptional repressor that represses the expression of genes associated with key components of TGF-β1 signaling pathway (Sabbah et al., 2011), which is the dominant pathway in fibrosis. Functional evidence showed that CCN5 inhibits smooth muscle cell (SMC) proliferation and motility while promoting a differentiated SMC phenotype (Sabbah et al., 2011). CCN5 also inhibits the epithelial-mesenchymal transition in breast and pancreatic cancer cells (Das et al., 2017). It is also known that TGF-β exerts biological activity by activating downstream mediators SMAD2 and SMAD3, and is negatively regulated by an inhibitory SMAD7 (Lan and Chung, 2011).

The PF-inducing factor bleomycin (BLM) is a bacterially-derived chemotherapeutic drug that induces DNA strand breakage and inhibits cell growth. BLM-induced lung fibrosis is the classical and most widely used mouse model system for studying fibrosis in the lung. BLM causes lung tissue damage primarily by inducing...
oxidant stress and inflammation, Low pulmonary levels of the detoxifying enzyme BLM hydroxylase result in drug persistence, which further promotes tissue damage (Liu et al., 2017). BLM models exhibit a massive inflammatory phase, leading to alveolar epithelial cell death and post-inflammatory lung fibrosis, followed by lung remodeling and gradual resolution (Liu et al., 2017). BLM induces fibrosis after intratracheal, subcutaneous, intravenous, intraperitoneal, or inhalational administration (B et al., 2013). For our study we chose systemic delivery of BLM via a subcutaneous route which is thought to simulate the processes in humans affected by bleomycin-induced fibrosis, through the vascular endothelium (Hashimoto et al., 2010). In contrast, intratracheal injections of BLM cause high mortality with heterogeneous and variable lung lesions (B et al., 2013; Ravanetti et al., 2020).

BLM lung toxicity is ameliorated by activation of the heme oxygenase-1/carbon monoxide (HO-1/CO) system (Hull et al., 2016; Otterbein, 2009; Suliman et al., 2007a, 2017). HO-1 is also protective in human idiopathic pulmonary fibrosis (Nakamura et al., 2011). Human HO-1 deficiency causes lung fibrosis (Bonnell et al., 2004), whereas HO-1 overexpression prevents lung fibrosis, in part by anti-apoptotic activity (Adedoyin et al., 2017). In BLM fibrosis (Tsuburai et al., 2002), HO-1 reduces the fibrosis, and its products, bilirubin and carbon monoxide (CO) contribute to less fibrosis (Zhou et al., 2005). The protective effects of CO and related pathways have led to the development of chemical CO-releasing molecules (CORMs), designed to reduce inflammation by delivering metered amounts of CO into tissue (Gullotta et al., 2012; Piantadosi, 2008), but without a distinct anti-fibrotic mechanism.

BLM lung toxicity is ameliorated by activation of the heme oxygenase-1/carbon monoxide (HO-1/CO) system (Hull et al., 2016; Otterbein, 2009; Suliman et al., 2007a, 2017). HO-1 is also protective in human idiopathic pulmonary fibrosis (Nakamura et al., 2011). Human HO-1 deficiency causes lung fibrosis (Bonnell et al., 2004), whereas HO-1 overexpression prevents lung fibrosis, in part by anti-apoptotic activity (Adedoyin et al., 2017). In BLM fibrosis (Tsuburai et al., 2002), HO-1 reduces the fibrosis, and its products, bilirubin and carbon monoxide (CO) contribute to less fibrosis (Zhou et al., 2005). The protective effects of CO and related pathways have led to the development of chemical CO-releasing molecules (CORMs), designed to reduce inflammation by delivering metered amounts of CO into tissue (Gullotta et al., 2012; Piantadosi, 2008), but without a distinct anti-fibrotic mechanism.

The HO-1/CO system regulates mitochondrial biogenesis (Piantadosi, 2008; Piantadosi et al., 2011). CO activates the redox-sensitive transcriptional program for mitochondrial quality control (MQC) through nuclear respiratory factor-1 (NRF-1), which is implicated in the mitigation of various injuries, including organ fibrosis, and inhibits ischemic and drug-induced cardiomyopathy, and sepsis-induced organ failure (Piantadosi et al., 2011; Suliman et al., 2003, 2007a; Suliman and Piantadosi, 2016). No studies exist that link the HO-1/CO system and MQC regulation through NRF-1 to PF. Our goal was to understand the anti-fibrotic effects of NRF-1 in mouse lung using a unique CORM (ReCORM) which delivers CO directly to cells and induces NRF-1 (Suliman and Piantadosi, 2016). In this study, we aimed to appraise the effect of NRF-1 induction by ReCORM in BLM-induced pulmonary fibrosis and specifically to evaluate the mechanism of participating in regulation of critical anti-fibrotic genes implicated in PF pathogenesis.

RESULTS

ReCORM reduces lung fibrosis in a BLM model

Lung tissue sections stained with H&E showed no changes in control (Vehicle treated) lungs; however, the alveoli are sharply demarcated, air-filled, and typical of an intact alveolar region (Figure 1A). Treatment with rhenium based CO-releasing molecules (ReCORM) alone has no adverse effects on mouse lung tissue, as visualized by H&E staining. By day 7 post-BLM treatment, the alveolar septa thickened and the lungs were infiltrated with inflammatory cells. BLM-treated mice that receive inactivated ReCORM (iCORM) are equally inflamed, but mice receiving active ReCORM show reduced cellular inflammation. By day 14, BLM-treated lung tissue showed some alveolar areas filled with loose connective tissue, and the alveoli were nearly devoid of air. However, the lungs of BLM-treated mice that received ReCORM appear normal with few inflammatory cells. This provides evidence that mouse lung tissue could be protected against BLM-induced damage by ReCORM.

Separate mouse lung sections stained for collagen with Masson’s trichrome, and for α-smooth muscle actin (SMA) with fluorescent α-SMA antibody showed minimal collagen staining in control lungs (Figures 1B, 1C, and 1D, respectively). The BLM-treated mouse lungs showed dense collagen deposits in the alveolar region by day 7, whereas BLM-treated mice that received ReCORM showed only a few, scattered strands of collagen along the alveolar septa, peribronchiolar, and perivascular regions (Figure 1B). The extent of fibrosis at day 7 after BLM administration, as a percentage of the total alveolar area, is 18.6%; however, this fell by four-fold to 5.6% after ReCORM treatment (P < 0.05) (Figure 1C). Prominent α-SMA staining is seen throughout the pulmonary alveolar regions of BLM-treated mice at day 7, whereas little α-SMA staining is seen at day 7 in the lungs of mice that received ReCORM (Figure 1D). To quantify the ability of ReCORM to reduce expression of lung profibrotic proteins Col1α1 and α-SMA in the lung after BLM treatment, we measured their expression by immuno blot. ReCORM caused appreciative decrease of these profibrotic proteins in BLM-treated mice (Figures 1E–1G).
ReCORM improves lung function

BLM treatment typically causes pulmonary restriction, and in this study, BLM caused loss of physiological lung compliance and increased airway resistance, as measured via Flexivent (Figures 1H and 1I). Pulmonary systemic compliance falls by about 42% (P < 0.05), whereas resistance increases by 68% on day 14. Treatment with ReCORM prevents this loss of lung function after BLM-induced lung injury, whereas iCORM has no effect.

ReCORM increases HO-1 and NRF-1 and decreases TGFβ1 and TGFβr1 proteins

The mouse model of BLM-induced lung fibrosis is widely utilized to study lung fibrosis, which is known to eventually resolve over time in young mice (Hecker et al., 2014). However, the mechanisms involved in stimulating fibrosis resolution are not well understood. ReCORM is safe and used to enhance mitochondrial biogenesis and quality control via induction of the HO-1/NRF-1 pathway (Suliman et al., 2016).

We explored whether ReCORM, via HO-1/NRF-1 pathway activation, can accelerate resolution of fibrosis in the bleomycin-induced lung fibrosis model. First, we showed that three doses of ReCORM increased protein expression of HO-1, NRF-1, Nrf2, and PGC-1α (Figures 2A–2D). Further, ReCORM caused significant reductions in several pro-fibrotic markers, including total lung TGFβ1 and TGFβr1 proteins, especially...
following BLM treatment. Marked upregulation of TGFβ1 by three-fold was observed with BLM, whereas active ReCORM essentially abolished this response (Figure 2E). Figure 2G shows immunoblot data for lung TGFβR1 protein levels pre-BLM and post-BLM, which impressively increased by three-fold (P < 0.05). ReCORM appears to have an independent effect on TGFβR1 protein levels, suppressing its protein expression to minimal values, almost blocking the effect of BLM (Figure 2H). The administration of iCORM has no effect on expression levels of these proteins.

We tested the effects of BLM on the expression of the pro-fibrotic proteins, fibronectin (FN), vimentin (VIM), and the epithelial adhesion marker, E-cadherin (E-cad). Figure 3A and scatter plots in Figures 3B–3D indicate that BLM increased FN and VIM expression, and decreased E-cad levels in the lungs. BLM did not activate the redox pathway for mitochondrial biogenesis, while it blunts NRF-1 expression along with TGFβ1 antagonists, CCN5, and SMAD7 (Figures 3E–3I). Meanwhile, ReCORM increases nuclear NRF-1 levels and prevents decline in CCN5 and SMAD7 expression and decreases phosphorylated Smad2 and 3 (pSmad2 and pSmad3) after BLM exposure. ReCORM alone stimulates the nuclear accumulation of NRF-1, as well as total CCN5 and SMAD7 levels in mouse lung tissue. Because these three proteins respond together, we postulate that they are linked.
ReCORM preserves mitochondrial function and decreases cell death after BLM exposure

Because the HO-1/NRF-1 pathway is linked to activation of mitochondrial biogenesis, we tested the effects of ReCORM treatment on mitochondrial function and cell survival. Mitochondrial injury is a key component of BLM injury; therefore, we used Seahorse technology to measure respiration and spare and total respiratory capacity in viable mouse lung epithelial type 2 (AT2) cells isolated by flow cytometry, and plated on eight-well plates (Lottes et al., 2014). Respiration quantified on the Seahorse XF platform is shown in Figure 3.
Figure 4A, where the spare respiratory capacity (rSRC) (relative to basal ATP-dependent respiration) of AT2 cells isolated from each group is shown; Figure 4B shows the maximal oxygen consumption rate (uncoupled, OCR). BLM alone significantly reduced rSRC and OCR as compared to the vehicle control treatment, whereas iCORM treated mice did not show a change in rSRC or OCR, but ReCORM treatment after BLM resulted in higher rSRC and OCR levels than those observed in the other three groups.

Some evidence suggests that other CORMs may alter respiration by affecting proton leak across the mitochondrial membrane (Reiter and Alayash, 2012), so we examined this in each group (Figure 4C). Exposure to BLM resulted in a significant increase in ETC proton leak as compared to the iCORM-treated group, which was reversed with ReCORM treatment. ETC proton leak, basal respiration, rSRC, or maximal respiratory capacity, as compared to control-treated animals at day 7, indicating no evidence of ReCORM-associated mitochondrial toxicity.

Alveolar epithelial cell death is essential for the progression of BLM-induced fibrosis. and lung TUNEL staining and caspase 3 cleavage (Figures 4D and 4E) showed no cytotoxicity because of treatment with ReCORM or iCORM, whereas BLM greatly increases TUNEL positivity in AT2 cells, with comparatively minor effects on the other epithelial cell types (Figure 4D), in accordance with the literature (Barkauskas et al., 2013; Parimon et al., 2020). BLM-induced cell death was obviously attenuated by ReCORM treatment.
Caspase 3 cleavage in mouse lung tissue, enhanced by BLM, is reduced by ReCORM, whereas iCORM or ReCORM treatment alone has no impact on cell death (Figures 4F and 4G). Furthermore, ReCORM decreased mtDNA lesions frequency following BLM treatment (Figure 4H).

We assessed mtDNA-encoded protein levels by immunoblot (Figure 4I) and showed that BLM exposure significantly depressed the levels of key mitochondrial proteins, Cytochrome c oxidase subunit 1 (COX1), Cytochrome b (Cytb), NADH-ubiquinone oxidoreductase chain 1 (ND1), and NADH dehydrogenase 1 alpha subcomplex assembly factor 1 (NDUFAF1, Figures 4J–4M). ReCORM, but not iCORM treatment, prevented loss of these mitochondrial proteins.

**ReCORM protects lung fibroblasts and alveolar epithelial cells during BLM treatment**

The presence of α-SMA-positive myofibroblast foci is a hallmark of lung fibrosis (Subramanian et al., 2004); therefore, we evaluated α-SMA accumulation in the human fibroblasts cell line, MRC5 (Aoki et al., 2005) using confocal immunofluorescence microscopy before and after BLM. BLM caused MRC5 cells to become elongated with flattened morphology, and increased α-SMA fiber formation, all of which were reduced by ReCORM (Figure 5A). Immunoblotting of pro-fibrotic and anti-fibrotic proteins in MRC5 cells indicates that exposure to BLM enhances α-SMA, and VIM levels over 48 h (Figures 5B–5D), but ReCORM decreases their expression, enhancing CCN5 and Smad7 driven anti-fibrotic protein levels (Figures 5E and 5F) and blunting phosphorylated Smad2 and 3 after BLM exposure (Figures 5G and 5H). TGFβ1 stimulates mitochondrial oxidant production in lung fibroblasts and alveolar epithelial cells, particularly by Complex III of the electron transport chain (Jain et al., 2013; Kurundkar and Thannickal, 2016; Li et al., 2020); therefore, we measured the effects of ReCORM treatment on mtDNA damage and lesion frequency in mouse lung post BLM treatment and in MRC5 cells following treatment with TGFβ1. Our results indicated that ReCORM decreases the mtDNA oxidative lesion frequency induced by TGFβ1 (Figure 5I).

In addition, we exposed MLE12 mouse lung epithelial cells to TGFβ1 or BLM, and measured cell levels of α-SMA by immunofluorescence 84 h later (Figure S1). Both BLM and TGFβ1 increased α-SMA levels in these cells, with these effects prevented by ReCORM treatment, but not with iCORM.

**ReCORM regulation of anti-fibrotic genes via NRF-1**

We screened the regulatory regions in the CCN5 and Smad7 loci by aligning sequence conservation for the human and mouse genes. We used web-based rVISTA to identify conserved sequences for specific transcription factors by linking them to the TRANSFAC database (Loots and Ovcharenko, 2004). Analysis of the region of mouse and human DNA, at 1kbp proximal sequence to the CCN5 and Smad7 genes 5'UTR (DNAsis and Genomatix), identified the canonical NRF-1 consensus within the conserved promoter sequences of these genes. A schematic of the CCN5 and Smad7 loci with expanded sequences is shown in Figures 6A and 6D, where the regions at −1000 to −10 of the mouse and human sequences upstream of the transcription start site (TSS) bear sequences identified with a high likelihood for NRF-1 binding by exhibiting 90-100% identity with the NRF-1 motif sequence, 5'- T/C GCGCA (T/C) GCGC (A/G-3'. ChiP-qPCR assays were used to examine whether NRF-1 bound directly to the putative consensus sites identified in the CCN5 and Smad7 promoters in mouse lung tissue, and MRC5 cells after BLM challenge with and without ReCORM treatment. A strong enrichment of NRF-1 bound to promoters of CCN5 and Smad7 in mouse lung (Figures 6B and 6E) and in MRC5 cells (Figures 6C and 6F) is observed in ReCORM treatment, especially within the conserved region of the promoters, confirming ReCORM enhancement of NRF-1 binding to both gene promoters.

To establish CCN5 and Smad7 as NRF-1 target genes, MRC5 cells were exposed to BLM, and CCN5 and Smad7 mRNA expression was measured by quantitative real-time RT-PCR. ReCORM enhanced CCN5 and Smad7 mRNA, whereas BLM alone decreased the expression of these two genes (Figures 7A and 7B). To examine the contribution of NRF-1 to CCN5 and Smad7 gene activation by ReCORM, MRC5 cells were transfected with control non-specific ShRNA (NS-ShRNA) or ShRNA targeting NRF-1 (Sh-NRF-1), and silencing efficacy was determined at 48 h (Figures 7C and 7D). After establishing an optimal protocol, the cell line was treated with BLM, ReCORM, or BLM + ReCORM for 24 h. The NS-ShRNA did not affect basal or ReCORM-induced CCN5 or Smad7 transcription, whereas knockdown of NRF-1 reduced basal and ReCORM-stimulated CCN5 and Smad7 mRNA levels by about half (Figures 7A and 7B).
Furthermore, we confirmed the ReCORM effects on cellular HO-1 (Figure 7E) and NRF-1 (Figure 7F) expression in a MRC5 cell line. ReCORM enhanced HO-1 and NRF-1 mRNA levels, and overcame the suppression of both messages by TGFβ1 as a surrogate for BLM. CCN5 overexpression markedly decreased α-SMA expression.
Figure 6. Bioinformatics analysis of mouse and human promoter regions of CCN5 and SMAD7. The corresponding sequences between human and mouse were aligned by rVISTA 2.0. The degree of interspecies conservation of the DNA within the 5'-UTR segment is represented by the histogram. CNS (interspecies conservation more than 75%) is emphasized in red.

(A) Conserved NRF-1, motifs on the human and mouse CCN5 gene were identified using the Genomatox and DNAis database, and are displayed with red stripes above the histograms.

(B) ChIP for occupancy of NRF1 on CCN5 promoters in BLM treated mouse lung with or without ReCORM.

(C) ChIP assays assessing DNA enrichment by NRF1 on CCN5 promoters in human lung fibroblasts incubated with BLM, with or without ReCORM.

(D) Human and mouse Smad7 promoter sequences were aligned and scanned for NRF-1 conserved motifs. Conservation plot diagrams are shown for each region, with conserved NRF1 sites displayed with red stripes above the histograms.

(E) NRF-1 occupancy on Smad7 promoter in BLM treated mouse lung with or without ReCORM and assessed by ChIP assay and displayed as histogram.

(F) NRF-1 occupancy on SMAD7 promoter in BLM treated MRC5 with or without ReCORM and assessed by ChIP assay and displayed as histogram. Values along the abscissa indicate positions of DNA regions amplified by qPCR. Green and blue bars depict significant DNA enrichment after ReCORM at positions indicated. Values represent the means ± SEM of independent experiments performed in triplicate. *P < 0.05 compared ReCORM with the iCORM group. (P < 0.05 ReCORM + BLM vs BLM groups).
levels induced by TGFβ1 (Figure 7G). Moreover, CCN5 knockdown caused noticeable upregulation of α-SMA mRNA levels (Figure 7G), supporting the hypothesis that CCN5 antagonizes the TGFβ1-induced pro-fibrotic phenotypic changes in these cells. To show that the CCN5 effect is dependent upon NRF-1.
expression, we used NRF-1 overexpression and silencing in MRCS cells, with and without TGFβ1 treatment (Figure 7H). The NRF-1 vector blocked the α-SMA response to TGFβ1, while NRF-1 silencing allowed α-SMA to respond. These data support a requirement for NRF-1 in the down-regulation of α-SMA mRNA levels after TGFβ1 exposure. The overexpression plasmids of CCN5 and NRF-1 efficacy were determined at 48 h (Figure S2).

ReCORM reduced lung inflammation due to BLM treatment

Oxidants and cytokines are important effectors of BLM toxicity due to drug persistence in alveolar type II cells, a primary target of BLM (Onuma et al., 1974). We assayed lung pro-inflammatory cytokine levels for IL-1β and Nlrp3 proteins, and the anti-inflammatory cytokine IL-10. Figure 8A shows immunoblots indicating the responses of all three of these proteins to BLM exposure at day 7. In Figures 8B–8D, densitometry of the immunoblots revealed that BLM increased IL-1β levels by six-fold relative to the control (Figure 8B), but this response is blocked by ReCORM. IL-10 is anti-inflammatory, and has been shown to reduce fibrosis in BLM-treated animals and in IPF patients (Wilson et al., 2010). As shown in Figure 8C, BLM treatment suppressed IL-10 levels by about 50%, while ReCORM restored IL-10 expression to pre-BLM levels, but not higher (Figure 8C). Nlrp3 levels increased four-fold after BLM, while ReCORM treatment significantly (P < 0.05) inhibited this rise (Figure 8D). The key nucleoprotein transcription factor involved in early-phase cytokine transcription, NFκβ-p65, also increased after BLM administration and suppressed

Figure 8. Post-BLM lung inflammation
(A) Immunoblot for pro-inflammatory proteins IL-1β, Nlrp3, and anti-inflammatory protein IL-10 after BLM administration (B–D). Scatterplots of densitometry analysis for IL-1β, IL-10, and Nlrp3. (E) Immunobots for the transcription factor NFκβ-p65. (F) Scatterplot of densitometry levels for nuclear NFκβ-p65 normalized to laminB. (G) Immunoblot of lung caspase 1 active protein p10. (H) Scatterplots of densitometry analysis for Caspase 1-p10. Semi-quantitative data are expressed as mean ± SD (n = 6/group). *P < 0.05 compared ReCORM with the iCORM group (†P < 0.05 ReCORM + BLM vs BLM group).
by ReCORM, and returned to close to normal levels after BLM plus ReCORM administration (Figures 8E and 8F). Because the NLRP3 inflammasome is a critical component of the innate immune system that mediates caspase-1 activation and the secretion of pro-inflammatory IL-1β/IL-18 in response to microbial infection and cellular damage, we measured caspase1 activation after BLM treatment. Caspase 1 was increased in the BLM treated group but was blunted in the ReCORM treated BLM group (Figures 8G and 8H) suggesting that the inflammasome pathway is interrupted by the CO/HO-1 pathway.

Anti-fibrotic effects of ReCORM require alveolar type 2 cell HO-1 expression

Levels of HO-1 and NRF-1 mRNA and protein expression are reduced after BLM administration in wild type (WT) mice (See Figures 2A, 2B, S3A, and S3B). Mice treated with ReCORM after BLM exhibit higher levels of HO-1 and NRF-1 mRNA and proteins in their lungs compared to mice treated with BLM alone, as shown in Figures 2A, 2B, S3A, and S3B. To determine whether the anti-fibrotic effects of ReCORM are mediated through HO-1 in mouse lung, we treated HO-1 conditional knockout (HO-1 CKO) (Suliman et al., 2017) mice with BLM. Mice lacking HO-1 in AT2 lung epithelial cells demonstrate significant and widespread lung fibrosis, as well as higher Col1a1, aSMA, pSmad2, pSmad3, and TGFβ1 proteins expression levels than WT littermates (Figures 9A–9G). Unlike WT littermates, ReCORM treatment after BLM did not improve fibrosis in HO-1CKO mouse lungs (Figure 9A). As a key regulator of mitochondrial quality control (Piantadosi et al., 2008; Suliman et al., 2007b), the loss of HO-1 in AT2 cells renders mice more susceptible to BLM-induced lung fibrosis, in part because of both a decrease in NRF-1 and Smad7 (Figures 9H and 9I) and a subsequent increase in pSmad2, 3, and TGFβ1 expression.

DISCUSSION

The HO-1/CO pathway has emerged as an important contributing factor in initiation and maintenance of mitochondrial quality control, as well as protection of lung tissue from injury because of oxidative stress (Piantadosi et al., 2011; Suliman and Piantadosi, 2016). Current therapies for the prevention of devastating loss of gas exchange during PF in humans have both major side effects and limited efficacy. Our data show that ReCORM decreased TGFβ1 and TGFβr1 in BLM treated mice. Therefore, we explored the interactions between the mitochondrial biogenesis transcriptional program and anti-fibrotic gene regulation. Here we confirmed that NRF-1 serves as a transcriptional activator of the CCN5 and SMAD7 genes via a mechanism involving CO and HO-1 that represses TGFβ1 and blocks the SMADs pathway.

Many CORMs are metal carbonyl compounds capable of delivering defined amounts of CO to cellular systems, thereby avoiding CO toxicity, and mimicking the biology of endogenous CO (Sawle et al., 2005; Suliman et al., 2016). They exhibit anti-inflammatory (Sawle et al., 2005), anti-proliferative (Kim et al., 2005; Schwer et al., 2010), and bactericidal properties (Nobre et al., 2007). ReCORM is a rhenium carbonyl that slowly releases CO, and we have shown that it enhances NRF-1 activity and stimulates mitochondrial biogenesis in mouse cardiomyocytes (Suliman et al., 2016). Here, we observed that ReCORM suppresses BLM-induced lung fibrosis by mitochondrial protection and by induction and activation of NRF-1 and its downstream target genes, CCN5 and Smad7 that are known antagonists of the TGFβ1 pro-fibrotic pathway.

Normally, BLM-induced lung fibrosis in mice develops in two phases (Chaudhary et al., 2006); the first occurs during the first 7 days after exposure, and it is characterized by inflammation in the parenchyma and airways. Fibrosis requires a second phase of pro-fibrotic mediator elaboration, which includes TGFβ1 (Chaudhary et al., 2006), a potent inducer of extracellular matrix deposition. Owing to the upregulation of anti-inflammatory factors, acute inflammation resolves by day 14; thereafter many alveoli become nearly obliterated with plugs of connective tissue, and evolution of the inflammatory response after BLM indicates a persistent, adaptive immune presence at 21 days (Bordag et al., 2020). Compared to other models of BLM induced lung injury, subcutaneous injections used in our study induced moderate but diffuse inflammatory infiltrates and lung fibrosis. Therefore, we chose this model to investigate the underlying mechanisms of lung fibrosis and search for new therapeutic targets.

The limitations of this approach include inability of the model in mice to fully simulate the spectrum of human clinical PF. Despite this, BLM-induced pulmonary fibrosis in vivo has been useful in the development of anti-fibrotic therapies (Kamio et al., 2018). Because different routes of BLM challenge induce different levels of lung fibrosis, discrepant observations among studies may occur. Furthermore, spontaneous resolution of BLM-induced pulmonary fibrosis is observed in young mice, but not in aged mice (Tashiro et al., 2017).
Figure 9. ReCORM fails to induce anti-fibrotic response in lung of BLM treated HO-1CKO mice

(A) Lung section images from four groups of mice compared by Masson’s trichrome staining for collagen (4x: scale bars 4 μM).

(B) Optical density changes in collagen-stained lung using NIS-Elements imaging software 5.2 (Nikon). The HO-1CKO mice were euthanized at 7 d post BLM with and without ReCORM and the lungs were homogenized for extracting Lung proteins and analyzed for fibrogenic proteins α-SMA, Col1a1, pSmad2, pSmad3, and TGFβ1 and the antifibrogenic proteins NRF-1 and Smad7.

(C–I) Scatterplots of densitometry analysis of lung proteins. N = 5 in each group. Quantitative data are expressed as mean ± SD. *p < 0.05 compared ReCORM with the iCORM injected group, |p| < 0.05 ReCORM + BLM vs BLM groups.
TGFβ1 is vital for the activation, proliferation, and differentiation of fibroblasts, the emergence of myofibroblastic cells (De Langhe et al., 2013), and deposition of extracellular matrix (Wolters et al., 2014). Hence, TGFβ1 blockade generally reduces fibrosis. Here, the levels of TGFβ1 and TGFβr1 protein expression in mouse lung after BLM and ReCORM are diminished and clearly dependent on HO-1 and NRF-1 induction. Nuclear NRF-1 activity promotes Smad7 gene expression, thus limiting Smad2/3 binding to TGFβ1 receptors. HO-1 and NRF-1 expression in lung AT2 cells is a requirement for effective ReCORM protection after BLM exposure. This ReCORM protection against BLM exposure is counteracted in both a lung AT2 cell HO-1 conditional knockout mouse model, and in human lung fibroblast cells.

PF patients show many apoptotic AT2 pneumocytes, consistent with established, epithelial injury-based fibrosis mechanisms (Barbas-Filho et al., 2001). Indeed, specific AT2 cell death leads to PF (Sisson et al., 2010), and during our studies, AT2 cell death after BLM exposure was reduced by ReCORM treatment. The spare respiratory capacity and ETC leak measurements in viable AT2 cells show high impact on respiration with BLM treatment, and ReCORM treatment reversed the respiration and limited ETC leak.

The NRF-1 dependent induction of the CCN5 gene, a negative regulator of TGFβ1 activity, is a new mechanism by which these proteins are expressed and α-SMA and collagen expression suppressed during fibrosis (Sabbah et al., 2011; Suliman et al., 2017). Lung CCN5 expression after BLM exposure requires NRF-1 and results in lower TGFβ1 expression presumably because TGFβ1 induces rapid translocation of its own receptors to the cell surface, thereby amplifying its own response. Moreover, TGFβ1 promotes TGFβr1 internalization, thus intensifying recycling (Duan and Derynck, 2019). NRF-1 is recruited to CCN5 promoter regions proximate to Sp1 binding sites, which are known to enhance promoter activity. High cellular CCN5 activity interferes with pro-fibrotic CCN2 binding and acts as a repressor of the TGFβr1 promoter (Sabbah et al., 2011). Inflammation in BLM-induced lung fibrosis (Williamson et al., 2015) is thought to be mediated by apoptotic macrophages, which enhance inflammation and fibrosis (Wang et al., 2003) by releasing TGFβ1 and TNF-α (Wang et al., 2003). In our studies, we observed that Nlrp3 expression activated by BLM is suppressed by ReCORM, but not by iCORM. Nlrrp3-mediated IL-1β and IL-18 production, and NLRP3 levels are controlled by NF-κB activity (Afonina et al., 2017). CO gas inhibits NF-κB activation in human embryonic kidney cells, human HepG2 cells, and human Monocytes, preventing NF-κB-driven inhibition of Smad7 promoter activity, possibly through the iκB inhibitor (Chhikara et al., 2009). Here, lung NF-κB activation after BLM exposure was inhibited by ReCORM treatment, but not by iCORM; therefore, inflammasome suppression by ReCORM may limit NF-κB activation and early-phase inflammation. However, data from our NRF-1 conditional knockout mouse model indicate that suppression of inflammation is not the most important effect of the drug.

ReCORM treatment has been shown to decrease vimentin levels, an intermediate filament protein, which may inhibit inflammasome activation (Verstraeten et al., 2016). NF-κB is also essential for fibroblast differentiation (Ichikawa et al., 2013), but inhibition of NF-κB and knockdown of NF-κB p65 actually increases HO-1 expression under TGFβ1 challenge, and inhibits TGFβ1-induced fibroblast proliferation (Krug et al., 2010). Inhibition of NF-κB in T cells attenuates progressive lung fibrosis (Fujimoto et al., 2007); therefore, the ReCORM effect on NF-κB and Nlrp3 may be an anti-TGFβ1 feature of the drug.

Lung α-SMA expression is a hallmark of myofibroblasts (Leask, 2010); thus, inhibition of myofibroblast proliferation and differentiation may attenuate PF (Bindu et al., 2017). In MRC5 cells, CCN5 expression is constitutively low, whereas CCN2 expression is high. CCN2 and CCN5 oppose each other, and the latter suppresses TGFβ1. CCN5 is involved in wound healing, repair, development, and angiogenesis by modulation of signaling via integrins, BMP4, VEGF, Notch, and WNT (Sabbah et al., 2011). In our studies, we have seen that the CCN5 gene is strongly regulated by NRF-1, directly linking a mitochondrial biogenesis transcriptional program to anti-fibrosis activities.
Smad7 stably associates with TGFβr1 to block access and phosphorylation of Smad2/3 (Nakao et al., 1997), and Smad7 induction and localization is critical for this inhibitory function (Hanyu et al., 2001). Here, we show that NRF-1 binds to the Smad7 promoter and enhances its expression, functionally manifesting as a profound decrease in lung collagen synthesis. Previously, TGFβ1 inhibitor decorin (Kolb et al., 2001), or Smad7 gene transfer have been known to limit BLM-induced pulmonary fibrosis (Nakao et al., 1999), thereby explaining why Smad7 is beneficial. Smad7 interacts with TGFβ1 receptors, while Smad2/3 stimulates collagen gene transcription (Massague and Wotton, 2000), and Smad7 insertion prevents transcriptional activation of type I procollagen gene expression in human fibroblasts, so we cannot rule out a direct effect of the ReCORM on fibroblasts.

In conclusion, we provide the first evidence that the NRF-1 transcription factor provides anti-fibrotic activity in lung fibrosis by inhibition of the TGFβ1 pathway. This mechanism involves HO-1 upregulation of NRF-1, and NRF-1 transactivation of the CCN5 and Smad7 gene promoter regions. Although relevance to human lung fibrosis is limited to the effects shown in human lung fibroblast cells, ReCORM may show therapeutic benefit in controlling fibrosis involving excessive TGFβ1 activity. In practice, CORMs are simple to administer, especially compared with CO gas, and they provide limited and highly tissue-specific delivery of CO (Motterlini et al., 2002). This approach for mitigation of lung fibrosis by targeting the HO-1/NRF-1 pathway is broadly testable in the future.

Limitations of the study

Limitations of this study include the inability of BLM model to fully simulate the spectrum of human PF. Despite this, BLM-induced pulmonary fibrosis has been used in the development of anti-fibrotic therapies (Kamio et al., 2018). Because different routes of BLM challenge induce different levels of lung fibrosis, discrepant observations among studies may occur. In addition, spontaneous resolution of BLM-induced pulmonary fibrosis is observed in young mice, but not in aged mice (Tashiro et al., 2017). Our goal was to appraise the effect of NRF-1 induction by means of a pre-clinical drug, ReCORM, in BLM-induced pulmonary fibrosis and evaluate the mechanisms of regulation of critical anti-fibrotic genes.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Animal model
  - Cell lines
- METHOD DETAILS
  - Reagents
  - Studies of AT2 cell conditional HO-1 knockout mice
  - Lung function
  - Cell culture studies
  - Cell transfection
  - Quantitative real-time PCR
  - Mitochondrial DNA damage assay
  - Histology and confocal microscopy
  - Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay
  - Immunoblot analysis
  - AT2 cell isolation and Seahorse measurements
  - ChIP analysis
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.isci.2021.103535.
ACKNOWLEDGMENTS

We appreciate the technical assistance of Kathy Stempel, Martha Salinas, Kristina Porter, and Linhua Song. The authors thank Dr. John E. Baatz of the Department of Pediatrics, Medical University of South Carolina (MUSC) for insight discussion and technical assistance in developing the murine AT2 cellular respiration experiments. This work was supported by NIH grants R01-AI095424 and VA Merit Review grant to CAP, and by NIH grant K08-HL130557 (BDK).

AUTHOR CONTRIBUTIONS

HBS, CAP, KWW, and BDK conceptualized and designed experiments, collected and assembled data, analyzed and interpreted data, and wrote the manuscript.

FZ provided study material used for experiments. ZH, JS, and CB developed methodology, performed experiments, and collected and assembled data. All authors approved the final draft of the manuscript.

DECLARATION OF INTERESTS

The authors have declared that no competing interests exist.

Received: March 4, 2021
Revised: September 2, 2021
Accepted: November 25, 2021
Published: January 21, 2021

REFERENCES

Acedoyn, O., Boddu, R., Traylor, A.M., Lever, J.M., Bolssetty, S., George, J., and Agarwal, A. (2017). Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am. J. Physiol. Ren. Physiol. 314, F702–F714.

Afonina, I.S., Zhong, Z., Karin, M., and Beyaert, R. (2017). Limiting inflammation-the negative regulation of NF-κappaB and the NLRC3 inflammasome. Nat. Immunol. 18, 861–869.

Aoki, F., Kurabayashi, M., Hasegawa, Y., and Kojima, I. (2005). Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am. J. Respir. Crit. Care Med. 172, 713–720.

B, B.M., Lawson, W.E., Oury, T.D., Sisson, T.H., Raghavendran, K., and Hogaboam, C.M. (2013). Animal models of fibrotic lung disease. Am. J. Respir. Cell Mol. Biol. 49, 167–179.

Barbas-Filho, J.V., Ferreira, M.A., Sesso, A., Kairalla, R.A., Carvalho, C.R., and Capelozzi, V.L. (2001). Evidence of type II pneumocyte apoptosis in the pathogenesis of idiopathic pulmonary fibrosis (IPF).usual interstitial pneumonia (UIP). J. Clin. Pathol. 54, 132–138.

Barkauskas, C.E., Cronce, M.J., Rackley, C.R., Bowie, E.J., Keene, D.R., Stripp, B.R., Randell, S.H., Noble, P.W., and Hogan, B.L. (2013). Type 2 alveolar cells are stem cells in adult lung. J. Clin. Invest. 123, 3025–3036.

Bindu, S., Pillai, V.B., Kanwal, A., Samant, S., Mutlu, G.M., Verdin, E., Dulin, N., and Gupta, M.P. (2017). SIRT3 blocks myofibroblast Differentiation and pulmonary fibrosis by preventing mitochondrial DNA damage. Am. J. Physiol. Lung Cell Mol. Physiol. 312, L68–L78.

Bonnel, M.R., Viner, G.A., Zander, D.S., Mandalapu, S., Kazemfar, K., Spears, L., and Beaver, T.M. (2004). Heme-oxygenase-1 expression correlates with severity of acute cellular rejection in lung transplantation. J. Am. Coll. Surg. 198, 945–952.

Bordag, N., Biasin, V., Schnegel, D., Valzana, F., Jandl, K., Nagy, B.M., Shama, N., Wygrecka, M., Kwapiszewska, G., and Marsh, L.M. (2020). Machine learning analysis of the bleomycin mouse model reveals the compartmental and temporal inflammatory pulmonary fingerprint. iScience 23, 101819.

Borgeson, E., Docherty, N.G., Murphy, M., Rodgers, K., Ryan, A., O’Sullivan, T.P., Guiry, P.J., Goldschmeding, R., Higgins, D.F., and Godson, C. (2011). Lipoxin A(4) and benzo-lipoxin A(4) attenuate experimental renal fibrosis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 25, 2967–2979.

Casalena, G., Daehn, I., and Bottinger, E. (2012). Transforming growth factor-beta, bioenergetics, and mitochondria in renal disease. Semin. Nephrol. 32, 295–303.

Chaudhary, N.I., Schnapp, A., and Park, J.E. (2006). Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care Med. 173, 769–776.

Chihikara, M., Wang, S., Kern, S.J., Ferreyra, G.A., Baro, J.J., Munson, P.J., and Danner, R.L. (2009). Carbon monoxide blocks lipopolysaccharide-induced gene expression by interfering with proximal TLR4 to NF-kappaB signal transduction in human monocytes. PloS one 4, e8139.

Das, A., Dhar, K., Maity, G., Sarkar, S., Ghosh, A., Haque, I., Dhar, G., Banerjee, S., and Banerjee, S. K. (2017). Deficiency of CCN5/WISP-2 Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth. Sci. Rep. 7, 1220.

De Langhe, E., Cailotto, F., De Vooght, V., Aznar-Lopez, C., Vanoorbeek, J.A., Luyten, F.P., and Lories, R.J. (2015). Enhanced endogenous bone morphogenetic protein signaling protects against bleomycin induced pulmonary fibrosis. Respir. Res. 16, 38.

Duan, D., and Derynick, R. (2019). Transforming growth factor-beta (TGF-beta)-induced up-regulation of TGF-beta receptors at the cell surface amplifies the TGF-beta response. J. Biol. Chem. 294, 8490–8504.

Fujimoto, H., D’Alessandro-Gabazza, C.N., Palanki, M.S., Erdman, P.E., Takagi, T., Gabazza, E.C., Bruno, N.E., Yano, Y., Hayashi, T., Tamaki, S., et al. (2007). Inhibition of nuclear factor-kappaB and galectins attenuates bleomycin-induced lung fibrosis. J. Immunol. 179, 570–579.

Funke, M., Zhao, Z., Xu, Y., Chun, J., and Tager, A.M. (2012). The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am. J. Respir. Crit. Care Med. 176, 1251–1260.

Gazdar, A., Lebrecht, D., Roth, M., Tamm, M., Venhoff, N., Fookhooren, C., Geser, T., and Walker, U.A. (2014). Time-dependent and somatically acquired mitochondrial DNA mutation and respiratory chain dysfunction in a scleroderma model of lung fibrosis. Sci. Rep. 4, 5336.

Gorowiec, M.R., Borthwick, L.A., Parker, S.M., Kirby, J.A., Saretzki, G.C., and Fisher, A.J. (2012). Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a TGF-beta1-dependent mechanism. Free Radic. Biol. Med. 52, 1024–1032.

Guilotta, F., di Masi, A., Coletta, M., and Ascenzi, P. (2012). CO metabolism, sensing, and signaling. BioFactors 38, 1–13.
transcriptional control by the TGF beta/Smad signaling pathway. Mol. Cell. Biol. 19, 1459–1469.

Liu, T., De Los Santos, F.G., and Phan, S.H. (2017). The bleomycin model of pulmonary fibrosis. Methods Mol. Biol. 1627, 27–42.

Loots, G.G., and Ovcharenko, I. (2004). TF-BLAST: evolutionary analysis of transcription factor binding sites. Nucleic Acids Res. 32, W217–W221.

Lottes, R.G., Newton, D.A., Spyropoulos, D.D., and Baat, J.E. (2014). Alveolar type II cells maintain bioenergetic homeostasis in hypoxia through metabolic and molecular adaptation. Am. J. Physiol. Lung Cell Mol. Physiol. 306, L947–L955.

Massague, J., and Wotton, D. (2000). Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19, 1745–1754.

Motterlini, R., Clark, J.E., Foresti, R., Sarathchandra, P., Mann, B.E., Green, C.J., and Piantadosi, C.A. (2008). Carbon monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ. Res. 90, E17–E24.

Nakamura, T., Matsuoka, M., Hayashi, Y., Shibasaki, M., Imaizumi, K., Hashimoto, N., Shimokata, K., Hasegawa, K., and Watabe, T. (2011). Attenuation of transforming growth factor-beta-stimulated collagen production in fibroblasts by quercetin-induced heme oxygenase-1. Am. J. Respir. Cell Mol. Biol. 44, 614–620.

Nakao, A., Afrahnite, M., Moren, A., Nakayama, T., Christian, J.L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.E., Heldin, C.H., et al. (1997). Identification of Smad7, a TGF-beta-inducible antagonist of TGF-beta signalling. Nature 389, 631–635.

Nakao, A., Fujii, M., Matsumura, R., Kumano, K., Saito, Y., Miyazato, K., and Iwamoto, I. (1999). Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest. 104, 5–11.

Nobre, L.S., Seixas, J.D., Romao, C.C., and Saraiva, L.M. (2007). Antimicrobial action of carbon monoxide-releasing compounds. Antimicrob. Agents Chemother. 51, 4303–4307.

Onuma, T., Holland, J.F., Masuda, H., Waligunda, J.A., and Goldberg, M.A. (1974). Microbiological assay of bleomycin: inactivation, tissue distribution, and clearance. Cancer 33, 1230–1238.

Otterbein, L.E. (2009). The evolution of carbon monoxide into medicine. Respir. Care 54, 925–932.

Parimom, T., Yua, C., Stripp, B.R., Noble, P.W., and Chen, P. (2000). Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int. J. Mol. Sci. 1, 2269.

Piantadosi, C.A., (2008). Carbon monoxide, reactive oxygen signaling, and oxidative stress. Free Radic. Biol. Med. 45, 562–569.

Piantadosi, C.A., Carraway, M.S., Babiker, A., and Suliman, H.B. (2008). Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ. Res. 103, 1232–1240.

Rangarajan, S., Bernard, K., and Thannickal, V.J. (2017). Mitochondrial dysfunction in pulmonary fibrosis. Ann. Am. Thorac. Soc. 14, S383–S388.

Ravantei, F., Ragonieri, L., Ciccoiarr, R., Ruscetti, F., Porompilo, D., Gazz, F., Villetti, G., Cacchiotti, A., and Stellan, F.F. (2020). Modeling pulmonary fibrosis through bleomycin delivered by osmotic minipump: a new histomorphometric method of evaluation. Am. J. Physiol. Lung Mol. Physiol. 318, L376–L385.

Reiter, C.E., and Alayash, A.I. (2012). Effects of carbon monoxide (CO) delivery by a CO donor or hemoglobin on vascular hypoxia inducible factor 1alpha and mitochondrial respiration. FEBS Open Bio 2, 113–118.

Rock, J.R., Barkauskas, C.E., Cronce, M.J., Xue, Y., Harris, J.R., Lian, J., Noble, P.W., and Hogan, B.L. (2011). Multiple stomal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A 108, E1475–E1483.

Sabaiah, M., Pruner, C., Ferrand, N., Megalospanos, V., Lambeen, K., Oe Wever, O., Nazaret, N., Lacher, J., Dumont, S., and Redeuth, G. (2011). CCNS, a novel transcriptional repressor of the transforming growth factor beta signaling pathway. Mol. Cell. Biol. 31, 1459–1469.

Sawie, P., Foresti, R., Mann, B.E., Johnson, T.R., Harris, J.R., Lian, J., Noble, P.W., and Hogan, B.L. (2001). Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc. Natl. Acad. Sci. U.S.A 108, E1475–E1483.

Scher, C.I., Mutschler, M., Stoll, P., Goebel, U., Humar, M., Hoetzell, A., and Schmidt, R. (2010). Carbon monoxide releasing molecule-2 inhibits pancreatic stellate cell proliferation by activating p38 mitogen-activated protein kinase/heme oxygenase-1 signaling. Mol. Pharmacol. 77, 660–669.

Semren, N., Venk, V., Korfie, M., Keller, I.E., Fernandez, J.E., Adler, H., Gunther, A., Eickelberg, O., and Meiners, S. (2015). Regulation of 26S proteasome activity in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 192, 1089–1101.

Sisson, T.H., Mendez, M., Choi, K., Subbotina, N., Couray, A., Cunningham, A., Dave, A., Engelhardt, J.F., Liu, X., White, E.S., et al. (2010). Targeted injury of type II alveolar epithelial cells...
induces pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 181, 254–263.

Subramanian, G., Schwarz, R.E., Higgins, L., McEnroe, G., Chakravarty, S., Dugar, S., and Reiss, M. (2004). Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype. Cancer Res. 64, 5200–5211.

Suliman, H.B., and Piantadosi, C.A. (2016). Mitochondrial quality control as a therapeutic target. Pharmacol. Rev. 68, 20–48.

Suliman, H.B., Carraway, M.S., Welty-Wolf, K.E., Whorton, A.R., and Piantadosi, C.A. (2003). Lipopolysaccharide stimulates mitochondrial biogenesis via activation of nuclear respiratory factor-1. J. Biol. Chem. 278, 41510–41518.

Suliman, H.B., Carraway, M.S., Ali, A.S., Reynolds, C.M., Welty-Wolf, K.E., and Piantadosi, C.A. (2007a). The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine cardiomyopathy. J. Clin. Invest. 117, 3730–3741.

Suliman, H.B., Carraway, M.S., Tatro, L.G., and Piantadosi, C.A. (2007b). A new activating role for CO in cardiac mitochondrial biogenesis. J. Cell Sci. 120, 299–308.

Suliman, H.B., Zobi, F., and Piantadosi, C.A. (2016). Heme oxygenase-1/carbon monoxide system and embryonic stem cell differentiation and maturation into cardiomyocytes. Antioxid. Redox Signal. 24, 345–360.

Suliman, H.B., Keenan, J.E., and Piantadosi, C.A. (2017). Mitochondrial quality-control dysregulation in conditional HO-1/- mice. JCI Insight 2, e89676.

Tashiro, J., Rubio, G.A., Limper, A.H., Williams, K., Elliot, S.J., Nimou, I., Aidinis, V., Tzouvelekis, A., and Glassberg, M.K. (2017). Exploring animal models that resemble idiopathic pulmonary fibrosis. Front. Med. (Lausanne) 4, 118.

Tsuburai, T., Suzuki, M., Nagashima, Y., Suzuki, S., Inoue, S., Hasiba, T., Ueda, A., Ikehara, K., Matsuue, T., and Ishigatsubo, Y. (2002). Adenovirus-mediated transfer and overexpression of heme oxygenase 1 cDNA in lung prevents bleomycin-induced pulmonary fibrosis via a Fas-Fas ligand-independent pathway. Hum. Gene Ther. 13, 1945–1960.

Verstraeten, T., Cohet, C., Dos Santos, G., Ferreira, G.L., Bollaerts, K., Bauchau, V., and Shinde, V. (2016). Pandemrix and narcolepsy: a critical appraisal of the observational studies. Hum. Vaccin. Immunother. 12, 187–193.

Wang, L., Antonini, J.M., Rojasasakul, Y., Castranova, V., Scabilloni, J.F., and Mercer, R.R. (2003). Potential role of apoptotic macrophages in pulmonary inflammation and fibrosis. J. Cell. Physiol. 194, 215–224.

Williamson, J.D., Sadovsky, L.R., and Hart, S.P. (2015). The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Exp. Lung Res. 41, 57–73.

Wilson, M.S., Madala, S.K., Ramalingam, T.R., Gochuico, B.R., Rosas, I.O., Cheever, A.W., and Wynn, T.A. (2010). Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 207, 535–552.

Wolters, P.J., Collard, H.R., and Jones, K.D. (2014). Pathogenesis of idiopathic pulmonary fibrosis. Annu. Rev. Pathol. 9, 157–179.

Wu, W.A., Agostini, C., Antoniou, K.M., Bouros, D., Chambers, R.C., Cottin, V., Egan, J.J., Lambrecht, B.N., Lories, R., Parfrey, H., et al. (2013). The pathogenesis of pulmonary fibrosis: a moving target. Eur. Respir. J. 41, 1207–1218.

Wynn, T.A. (2011). Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208, 1339–1350.

Yadav, H., Quijano, C., Kamaraju, A.K., Gavrilova, O., Malek, R., Chen, W., Zerfas, P., Zhiqiang, D., Wright, E.C., Stuelten, C., et al. (2011). Protection from obesity and diabetes by blockade of TGF-beta/Smad3 signaling. Cell Metab. 14, 67–79.

Yeung, M., Hurren, R., Nemr, C., Wang, X., Hershfield, S., Gronda, M., Liyanage, S., Wu, Y., Augustine, J., Lee, E.A., et al. (2015). Mitochondrial DNA damage by bleomycin induces AML cell death. Apoptosis: Int. J. Program. Cell Death 20, 811–820.

Yoon, Y.S., Lee, J.H., Hwang, S.C., Choi, K.S., and Yoon, G. (2005). TGFbeta1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells. Oncogene 24, 1895–1903.

Zhou, Z., Song, R., Fattman, C.L., Greenhill, S., Alber, S., Oury, T.D., Choi, A.M., and Morse, D. (2005). Carbon monoxide suppresses bleomycin-induced lung fibrosis. Am. J. Pathol. 166, 27–37.

Zobi, F., Blacque, O., Jacobs, R.A., Schaub, M.C., and Bogdanova, A.Y. (2012). 17 e-rhenium dicarbonyl CO-releasing molecules on a cobalamin scaffold for biological application. Dalton Trans. 41, 370–378.
### STAR★METHODS

#### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| SPC                 | Santa Cruz Biotechnology Inc. | RRID: sc-13040 |
| HO-1                | Enzo Life Sciences | RRID: BML-HC3001 |
| NRF-1               | This paper | NA |
| PGC-1α              | Abcam | RRID: ab54481 |
| E-cad               | Santa Cruz Biotechnology Inc. | RRID: sc-18813 |
| α-SMA               | Cell Signaling Technology | RRID: 41085 |
| Col1α1              | Cell Signaling Technology | RRID: 8025 |
| Smad7               | Santa Cruz Biotechnology Inc. | RRID: sc130968 |
| Smad2/3             | Cell Signaling Technology | RRID: 37385 |
| Fibronectin         | Santa Cruz Biotechnology Inc. | RRID: sc-69681 |
| Vimentin            | Santa Cruz Biotechnology Inc. | RRID: sc-7557 |
| Nlrp3               | Abcam | RRID: ab98151 |
| IL-1B               | Abcam | RRID: ab2105 |
| IL-10               | Abcam | RRID: ab9965 |
| Casp3               | Cell Signaling Technology | RRID: 9688 |
| P65                 | Cell Signaling Technology | RRID: 8242 |
| ND1                 | Santa Cruz Biotechnology Inc. | RRID: sc-293243 |
| NDUFAF1             | Abcam | RRID: ab198186 |
| Cytb                | Abcam | RRID: ab181848 |
| COX1                | Santa Cruz Biotechnology Inc. | RRID: sc-23982 |
| TGF-β1              | Santa Cruz Biotechnology Inc. | RRID: sc-8829 |
| CCN5                | Santa Cruz Biotechnology Inc. | RRID: sc-25442 |
| TGFBR1              | Thermo Fisher Sci | RRID: PAS-32631 |
| Lamin B             | Santa Cruz Biotechnology Inc. | RRID: sc-374015 |
| Tubulin             | Sigma-Aldrich | RRID: T-5168 |
| Vdac                | Santa Cruz Biotechnology Inc. | RRID: sc-8829 |
| Secondary antibody  | Santa Cruz Biotechnology Inc. | RRID: sc-516102 |
| CD31                | eBioscience | RRID: 13-0311; |
| CD45                | eBioscience | RRID: 13-0451-82 |
| EpCAM-PE/Cy7        | eBioscience | RRID: 25-5791-80 |
| PE/Cy5 streptavidin | eBioscience | RRID: 405205 |
| Phospho-Smad2       | Cell Signaling Technology | RRID: 3108 |
| Phospho-Smad3       | Cell Signaling Technology | RRID: 9520 |
| **Chemicals, peptides, and recombinant proteins** | | |
| Human TGF-β         | R&D | RRID: 240-B; GenPept: P01137 |
| Bleomycin           | Millpore | RRID: 9041-93-4 |
| ReCORM              | This paper | Zobi et al. (2012) |
| **Experimental models: Cell lines** | | |
| Mouse: MLE-12       | ATCC | CRL-2110 |
| Human: MRC5         | ATCC | CCL-171 |

(Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding author, Dr. Hagir Suliman (Hagir.Suliman@duke.edu).

Materials availability
This study did not generate new unique reagents. Primers used are provided in Table S1 and available upon request to the corresponding author.

Data and code availability
The data reported in this paper will be shared upon request to the corresponding author. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animal model
Mouse studies were approved by the Duke University Medical Center Institutional Animal Care and Use Committee (IUCAC # A017-18-01). Male C57BL/6NJ mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Mice harboring a homozygous conditional null mutation in Hmox1fl/fl (Suliman et al., 2017) were crossed to transgenic Sftpc-CreERT2 mice (a gift from Dr. Brigid Hogan at Duke University) that express Cre recombinase under the control of the Sftpc promoter to generate AT2 pneumocyte-specific tamoxifen inducible HO-1 CKO mice. All work was done on a C57BL/6NJ background and Cre null littermates carrying the HO-1 floxed allele. Mice (5-7 per group) were used at 12–14 weeks of age (25 to 30 g) in this study. Mice were anesthetized using 0.3 mg xylene and ketamine (2.5 mg/kg i.p.) and gently inoculated subcutaneously with either bleomycin (5 mg/kg, Sigma-Aldrich; in 0.9% NaCl, 1 mg dry substance of BLM is equivalent to at least 1500 IU) with or without three consecutive doses of 1 mg/kg ReCORM (Suliman et al., 2016) at 6, 24, and 48 h. The negative control group received three consecutive doses (1 mg/kg) of iCORM in 0.9% NaCl (Suliman et al., 2016) or 0.9% NaCl as vehicle. The final group of mice received a single
dose of BLM at 5 mg/kg, followed by three consecutive treatments with ReCORM (1 mg/kg) at 6 h, 24 h and 48 h post BLM. Mice were sacrificed at 1- and 2- weeks post BLM exposure.

**Cell lines**
The mouse lung epithelial cell line MLE12, and human fibroblast cell line derived from fetal lung, MRC-5, were purchased from ATCC (Manassas, VA).

**METHOD DETAILS**

**Reagents**
All chemicals and reagents were purchased from Thermo Fisher Scientific unless otherwise indicated. ReCORM, a water-soluble CO-releasing molecule synthesized and characterized at the University of Zurich (Zobi et al., 2012), was used to enhance endogenous levels of CO. This agent increases cellular levels of CO without increasing carboxyhemoglobin by binding to B12 receptors and releasing two molecules of CO in about 20 minutes, along with one molecule of soluble ReO₄, which is stable nontoxic metal and cleared by the kidneys. The prodrug was dissipated in phosphate-buffered saline (PBS) for one to two hours before applying it to cells, or dissolved in 0.9% NaCl before injecting it into mice as inactivated ReCORM (iCORM). In each experiment we have used 6-10 mice per group. Dose ranging studies were performed in mice, and in MLE12 and MRC5 cells to identify ideal ReCORM concentrations that did not cause cell damage or death.

**Studies of AT2 cell conditional HO-1 knockout mice**
To selectively delete Hmox1 in lung AT2 cells, 8- to 10-week-old mice were given 10 mg/kg tamoxifen for 3 consecutive days. This produced rapid and effective knockdown of the targeted gene, HO-1. Eight days after tamoxifen administration, mice were injected with BLM with or without ReCORM and kept for 7 days and then euthanized. Lung tissues were harvested and used immediately or flash frozen and stored at −80°C for later use.

**Lung function**
Mice were deeply anesthetized and then paralyzed with intraperitoneal pentobarbital sodium (70–90 mg/kg, American Pharmaceutical) followed by pancuronium bromide (0.8 mg/kg Baxter) for measurements of lung system resistance and compliance by the single oscillation technique performed on a computer-controlled small animal ventilator (Flexivent System, SCIREQ) using a standardized protocol.

**Cell culture studies**
MLE12 cells were cultured in a CO₂ incubator (5% CO₂–95% air) at 37°C in Dulbecco’s modified Eagle’s medium: Nutrient Mixture F-12 (DMEM/F-12, Invitrogen), supplemented with 2% FBS, 100 unit/ml penicillin, 100 μg/ml streptomycin, 1% l-glutamine, 1% HEPES, 1% insulin/transferrin/sodium selenite, 0.01% β-estradiol, and 0.01% hydrocortisone. MRC-5 cells were maintained in minimum essential medium containing 10% FBS. All media were from Invitrogen (Carlsbad, CA). Cells were maintained at 37°C in a humidified incubator in the presence of 5% CO₂. Cell cultures were subsequently incubated for 24-84 hours in fresh media with transforming-growth-factor-beta 1 (rTGFβ1, Sigma) added at a concentration of 10 ng/ml. For further experimental control we tested the effect of iCORM alone and with BLM (Figure S4) which showed that iCORM +BLM did not differ from BLM alone for induction of TGFβ1.

**Cell transfection**
Cells were transfected in 6-well plates at 70%–80% confluence with pGFP-CRS vector containing HO-1 oligonucleotide sequence for optimal suppression of HO-1 (Origene, TR30018), NRF-1 (Origene, TFS17273) or CCNS (Origene, TFS11452). For overexpression, HO-1 TrueORF (Origene, MR203944), NRF-1 TrueORF (Origene, MG208550), or CCNS (Origene, RC204636) was used with FuGENE-HD (Promega, E2311). After 48–84 hours, the cells were harvested near confluence for further measurements. To confirm HO-1, NRF-1 or CCNS overexpression or knockdown, qPCR was used.

**Quantitative real-time PCR**
Total RNA was isolated from lung or cells using the RNAqueous-4 PCR kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Samples were treated with DNase I (4 units) for 1 hour at 37°C that
was then inactivated, and cDNA prepared with a high-capacity cDNA archive kit (Applied Biosystems), according to the manufacturer’s protocol. Primers for qRT-PCR for CCN5, HO-1, Nrf2, NRF-1, PGC-1α, α-SMA, Smad7 and 18S, obtained from Applied Biosystems, were used with the suggested protocol. All reactions were conducted on a StepOnePlus Sequence Detector System (Applied Biosystems) for 40 cycles. The results were analyzed using the 2−ΔΔCt method after normalization to the level of 18S expression in each sample. The relative quantitation method was used to analyze the results of two independent experiments done in triplicate.

**Mitochondrial DNA damage assay**
Genomic DNA was isolated using Qiagen Genomic-tip 20/G and Qiagen DNA Buffer Set (Qiagen, Gaithersburg, MD) per the manufacturer’s instruction. Final DNA pellet was resuspended in 10 mM Tris-HCl, pH 8.0. PCR was performed using LongAmp Hot Start Taq (New England Biolabs). Primer sequences for long fragment PCR (10 kb) are forward 5′-GCCAGCCTGACCCATAGC CATAATAT-3′; reverse 5′-GAGA GATTATGAGTG TAATGCGG-3′. Short fragment PCR (117 bp) was performed using forward primer sequence 5′-CCCAGCTACTACCATCATTCAAGT-3′, reverse primer 5′-GATGGTTTGG GAGATTGGTT GATGT-3′. Resultant PCR products were quantified using PicoGreen (Life Technologies). Values obtained from the long fragments were normalized using values from short fragments. The lesion frequency was calculated using the equation \( \lambda = -\ln \frac{AD}{AO} \), where \( AD/AO \) is the ratio of the amplification of damaged templates to the amplification of undamaged templates.

**Histology and confocal microscopy**
Hematoxylin and eosin (H&E), and Masson’s trichrome staining of lung tissue sections were conducted according to standard procedures (Suliman et al., 2017). Gross morphology was viewed under low-power (4X). Masson’s trichrome stain was used to evaluate lung fibrosis and extent of fibrosis was quantified by a blinded observer. Digitally captured images were analyzed with NIS-Elements imaging software (Nikon); collagen staining was quantified in 10 fields per section. Image analysis and quantification were performed in a blinded manner. To compare collagen stain intensities, the mean pixel intensities (1-mm-wide region-of-interest) were averaged to generate a mean value for each region. For immunofluorescence, sections were stained with citrate synthase (CS) primary antibodies (1:200; GeneTex Inc.), AT2 cell marker SPC (sc-13040), or α-SMA (Cell Signaling Technology, catalog 41085). The nuclei were stained with DAPI (Molecular Probes). Alexa Fluor–coupled secondary antibodies (Invitrogen) were used at 1:400. Stained sections were examined on a Zeiss LSM 710 laser-scanning confocal microscope. Fluorescent images were analyzed using NIS-element 5.2 software (Nikon). Negative controls were used to determine exposure times and prevent false positives.

**Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay**
Thin paraffin-embedded lung sections were used for the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay commercial kit (Cat. No. G3250; Promega) using the manufacturer’s instructions. Positive and negative control sections were prepared with either label solution only or by pre induction of strand breakage using recombinant DNase I. The reactions were terminated, and the slides were stained for surfactant protein C (SP-C; SC-13979; Santa Cruz Biotechnology) and treated with primary antibody followed by Alexa fluorescent secondary antibody (Alexa 488). Nuclei were counterstained with DAPI. Sections from four to five lungs in each group were stained, and at least five unique fields per section were quantified in each experiment by a blinded observer using Nikon image software (NIS element BR 5.2).

**Immunoblot analysis**
Protein extracts from mouse lung tissue (n = 4–6 per group) were analyzed by immunoblotting with a standardized approach (Suliman et al., 2017). Total lung protein, mitochondrial protein, or nuclear protein were resolved after fractionation by SDS-PAGE on gradient or 14% gels (Bio-Rad), transferred to polyvinylidene difluoride membranes (Millipore), blocked with 4% nonfat dry milk in Tris-buffered saline with Tween 20, and probed overnight at 4°C with antibodies against HO-1 (1:1,000; Enzo Life Sciences), NRF-1 (1:2,000, developed in our laboratory), PGC-1α (1:1,000; Abcam, ab54481), E-cad (1:1,000; Santa Cruz Biotechnology Inc., sc-18813), α-SMA (1:1,000; Cell Signaling Technology, Cat# 41085), Col1a1 (1:1,000; Cell Signaling...
Technology, Cat# 8025), Smad7 (1:500; Santa Cruz., sc130968), Smad2/3 (1:1,000; Cell Signaling 37385), fibronectin (1:500; Santa Cruz sc-69681), vimentin (1:500; Santa Cruz sc-7557), Nlrp3 (1:500; Abcam ab98151), IL-1β (1:500; Abcam ab2105), IL-10 (1:500; Abcam ab9965), Casp3 (1:1,000; Cell Signaling 9688), P65 (1:2000; Cell Signaling Technology, Cat# 8242), ND1(1:500; Santa Cruz sc-293243), NDUFAF1(1:500; Abcam, ab198186), Cytb (1:500; Abcam, ab181848), COX1 (1:500; Santa Cruz sc-23982), TGF-b₁ (1:500; Santa Cruz sc-8829), CCN5 (1:500; Santa Cruz sc-25442), or TGF-bR1 (Thermo Fisher Sci, PA5-32631). Protein loading was confirmed by nuclear protein Lamin B (SantaCruz sc-374015), tubulin (1:1000; Sigma-Aldrich, T-5168), or the mitochondrial Vdac (1:500; Santa Cruz sc-8829) and/or Coomassie Blue staining. After incubation with primary antibody, the membranes were treated with horseradish peroxidase–conjugated secondary antibody (1: 2,000, Santa Cruz sc-516102) and developed by enhanced chemiluminescence (Western Blotting Luminol Reagent, Santa Cruz). The protein bands were quantified on digitized images in the mid-dynamic range using Quantity One (Bio-Rad). Densitometry measurements were normalized to tubulin, Vdac, Lamin B, or Coomassie in the same samples.

**AT2 cell isolation and seahorse measurements**

On day 7 following BLM exposure with or without ReCORM or vehicle treatment, C57BL/6NJ mice were euthanized and the lungs were dissected. AT2 cells isolation, mouse lungs were dissociated as described previously (Rock et al., 2011). Briefly, lungs were digested with dispase (Corning) and 0.1 mg/mL DNase I. Red blood cells were removed using 1x BD Pharm Lyse solution (BD Biosciences), cut into small pieces (<2 mm²), and incubated in 1–2 mL protease solution for 25 min at 37°C with frequent agitation. DMEM/F12 + 10% FBS was added, and tissue was disrupted by pipetting, washed with DMEM/F12, and incubated for 20 min at 37°C in 2 mL0.1% Trypsin-EDTA + 0.325 mg DNase I with intermittent agitation. After filtering through a 40-µm strainer, cells were washed with 5 mL DMEM/F12. Antibodies for mouse flow cytometry were optimized with appropriate IgG isotype controls and were as follows: rat, CD31-biotinylated (1:50, #13-0311; eBioscience); rat, CD45-biotinylated (1:200; #13-0451-82; eBioscience); and rat, EpCAM-PE/Cy7 (1:800, #25-5791-80; eBioscience). Secondary antibody was as follows: PE/Cy5 streptavidin (1:500, #405205; Biolegend). Sorting was performed on FACS Vantage SE, and data were analyzed with FACS Diva (BD Biosciences). The purity of isolated AT2 cells was confirmed by the Papanicolaou stain, immunofluorescence staining with anti-proSP-C antibody. Optimization experiments were performed using MLE12, and murine AT2 cells to determine cell seeding density, reagent concentrations, and to ensure no interference from fluorophores present for sorting. After sorting, murine AT2 cells were counted and viability was determined by trypan blue exclusion. Cells were re-suspended in Seahorse DMEM media supplemented with 1 mM pyruvate, 2 mM glucose, 7.5 mM glucose, 1 mM HEPES, 5% HI-FBS, and 1x ITS supplement (R&D systems; MN, USA), and plated in XFp culture plates coated with CellTak (Corning, NY, USA) at a concentration of 5x10³ viable cells/well, and rested for 60 minutes at 37°C. Cellular respiration parameters were determined by sequential injection of oligomycin (1.5 mM), FCCP (0.5 mM and then 0.5 mM for a total of 1 mM), and rotenone/antimycin A (0.5 mM each). Data were normalized to total DNA content per well using the Qubit 3.0 HS DNA Assay (Thermo Fisher Scientific; MA, USA).

**ChIP analysis**

ChIP assays were performed in MRC5 cells or lung isolated nuclei. Cells or lung nuclei were treated with 0.4% formaldehyde and lysed, and the retrieved nuclei were snap frozen in a mixture of isopropanol and dry ice. Frozen nuclei were subsequently pooled and lysed. ChIP assays were performed as previously described (Suliman et al., 2017). Nuclei were sonicated in shearing buffer. Shearing effectiveness was confirmed by electrophoresis on ethidium bromide-stained agarose gels. Samples were processed for immunoprecipitation using ChIP IT assay kit (Active Motif) and NRF-1 antibody (Piantadosi et al., 2008) at a concentration of 2–5 µg/ml. The enrichment of CCNS and Smad7 promoters with NRF-1 was evaluated by quantitative real-time PCR (qPCR) in 20 µl mixtures of SYBR Green master mix and 0.1 µmol/L primer. Primers for regions upstream of the mouse CCNS or Smad7 promoter regions (sequences available on request) were used. The relative efficiency of each primer pair was determined using input DNA and adjusted accordingly. DNA in each ChIP sample was normalized to the corresponding input chromatin (ΔΔCt) and enrichment defined as change in Ct in ReCORM treated versus untreated control samples (ΔΔΔCt), relative to IgG. Exponential ΔΔCt values were converted to linear values (2-ΔΔCt) for graphics.
QUANTIFICATION AND STATISTICAL ANALYSIS
The results are expressed as mean ± S.D. Analysis was performed after a normality test. Data from multiple groups were compared by two-way ANOVA. Fisher’s Protected Least Significant Difference (LSD) tests were used for post-hoc analysis. The Wilcoxon rank-sum test was performed where data were not normally distributed. Values of P < 0.05 were considered significant.